Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 39 member 3 (SLC39A3), also known as ZIP3, is a member of the ZIP family of zinc transporters that facilitates the uptake of zinc into the cytoplasm from either the extracellular environment or intracellular compartments[1][2][3][6][7]. ZIP3 is an eight-transmembrane domain protein expressed in a tissue-selective manner, with prominent expression in secretory tissues such as the prostate, pancreas, mammary gland, testis, and certain regions of the brain (including hippocampus and cortex)[1][2][4][5]. In glandular tissues, ZIP3 helps accumulate zinc at the cellular level, which is essential for tissue-specific function, and loss of ZIP3 is observed in certain cancers, implicating it in tumor suppression and early neoplastic transformation[1][2]. In the mammary gland, ZIP3 plays a key role in the reuptake and retention of zinc from secreted milk rather than dietary acquisition, with effects on apoptosis and tissue morphology[4][5]. The protein acts as a transporter at the plasma and intracellular membranes and is vital for maintaining zinc homeostasis, a function critical for numerous cellular processes including immune regulation and possibly neural development[1][3][5][7]. No specific drugs are currently known to target SLC39A3 directly. Downregulation of SLC39A3/ZIP3 may serve as a biomarker for early detection in some cancers, particularly of the prostate and pancreas[2]. Disturbed zinc homeostasis from altered SLC39A3 function could represent a therapeutic challenge, particularly in tissues that are sensitive to changes in zinc concentration[4][5].
Not established for any drugs; generally, modulation of SLC39A3 would alter cellular zinc uptake
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 39 member 3 (SLC39A3).